Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
life sciences
national blog main
san francisco blog main
boston blog main
boston top stories
cancer
clinical trials
national top stories
new york blog main
san diego blog main
san francisco top stories
astellas pharma
deals
raleigh-durham blog main
san francisco
sanofi
seattle blog main
seattle top stories
vertex pharmaceuticals
10x genomics
american society of clinical oncology (asco)
anti-inflammatory drugs
arcturus therapeutics
atlas venture
audentes therapeutics
avidity biosciences
avrobio
becton dickinson
bluebird bio
boston
boulder/denver blog main
boulder/denver top stories
brexanolone
camp4 therapeutics
cancer diagnostics
cancer drugs
cancer immunotherapy
colorectal cancer
crispr therapeutics
What
reach
4
×
cancer
drug
ipo
medicines
adding
ago
ahead
aims
ambien
american
annual
asco
attendees
attention
biotech
biotechs
camp’s
cancer’s
cash
chicago
city
clinical
combinations
community’s
company
considering
data
days
deal
decisions
diagnostic
diagnostics
disease
diseases
dyne
early
expand
expanding
expected
Language
unset
Current search:
reach
×
biotech
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
